Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Special Features of Adaptive Immunity01:20

Special Features of Adaptive Immunity

2.9K
The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
2.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
T Cell Types and Functions01:24

T Cell Types and Functions

2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

15.8K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
15.8K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.4K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.

Journal for immunotherapy of cancer·2026
Same author

Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma.

Journal for immunotherapy of cancer·2026
Same author

Effects of Vemurafenib ± Cobimetinib on Intratumoral and Host Immunity in Patients With BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy.

Cancer medicine·2026
Same author

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.

CA: a cancer journal for clinicians·2025
Same author

Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047.

Journal for immunotherapy of cancer·2025

相关实验视频

Updated: Jan 9, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.2K

差异化甲状腺癌与性别特异性免疫反应有关

Leila Shobab1, Jennifer Simpson2, Matthew McCoy3

  • 1Department of Medicine, Division of Endocrinology, MedStar Washington Hospital Center, Washington, DC 20010, USA.

Journal of the Endocrine Society
|December 8, 2025
PubMed
概括

患有甲状腺癌 (TC) 的男性具有更具免疫抑制性的瘤微环境 (TME),具有更高的分裂自然杀手 (NK) 细胞和表达Tigit的CD8T细胞. 了解免疫细胞中的这些性别差异对于开发有针对性的TC疗法至关重要.

关键词:
甲状腺癌的性别差异甲状腺癌的免疫反应甲状腺癌瘤微环境

更多相关视频

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.4K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.4K

相关实验视频

Last Updated: Jan 9, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.2K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.4K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.4K

科学领域:

  • 免疫学 免疫学 免疫学
  • 在瘤学瘤学.
  • 基因组学就是基因组学.

背景情况:

  • 甲状腺癌 (TC) 在发病率,进展和患者结局方面表现出严重的基于性别的差异.
  • 在生育年龄的女性中,与TC的男性相比,她们的预后通常更为有利.
  • 这项研究重点是阐明TC患者的外周血液和瘤微环境 (TME) 中免疫细胞动态中的性别差异.

研究的目的:

  • 在甲状腺癌的TME中研究和比较性别特异性免疫细胞组成和基因表达特征.
  • 确定免疫细胞频率的潜在基于性别的差异及其在TC的功能影响.
  • 探索免疫相关基因表达在TC中观察到的性别差异中的作用.

主要方法:

  • 一项前性研究涉及27名患者 (16名女性,11名男性) 接受甲状腺切除术,以治疗TC或高风险结节.
  • 使用流细胞计和空间转录学,对采集的组织和血液样本进行免疫细胞分析.
  • 使用DESeq2对免疫相关基因的差异性基因表达分析和性别之间的免疫细胞频率比较.

主要成果:

  • 男性在TME中表现出更高的自然杀手 (NK) 细胞和Tigit+ CD8 T细胞分裂频率.
  • 女人表现出一种趋势,即成熟NK细胞和CD8T细胞的频率更高.
  • 与女性相比,空间转录组学揭示了男性的HLA-DRB表达 (抗原呈现) 减少以及TME中LAG3,IFNAR1,CD68和B2M的差异表达.

结论:

  • 在TC TME中存在免疫细胞组成和基因表达的显著性别差异.
  • 男性呈现出更强的免疫抑制特征,其特征是更高的抑制性免疫标记物和更低的功能NK细胞频率.
  • 纳入性别特异性免疫特征对于开发针对高级TC的向疗法至关重要.